Editas Medicine Licenses Genome Editing Technology From Duke University

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a leading genome editing company, today announced that they have entered into an exclusive license agreement with Duke University to access intellectual property and technology related to the CRISPR/Cas9 and TALEN genome editing systems. The license allows broad utilization of the technology developed in the laboratory of Charles Gersbach, Ph.D., for the prevention or treatment of human disease.

Help employers find you! Check out all the jobs and post your resume.